Anastrozole NDC 72789-575

NDC codes

FDA NDC Directory

Product NDC (as listed)72789-575Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72789-0575Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72789-575-15	72789057515	15 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72789-575-15)Marketed from Jun 22, 2026
72789-575-30	72789057530	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72789-575-30)Marketed from Aug 5, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Anastrozole
Generic name (nonproprietary): anastrozole
Active ingredients: Anastrozole — 1 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: PD-Rx Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212434
Marketing start: Jun 22, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Aromatase Inhibitors (Mechanism)
Identifiers: Product ID 72789-575_585069f8-4571-1711-e063-6394a90a9186SPL ID 585069f8-4571-1711-e063-6394a90a9186SPL set ID 54da5c12-cfaf-7a14-e063-6394a90a3635RxCUI 199224UNII 2Z07MYW1AZUPC 0372789575155
Pharmacologic class: Aromatase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472789057515 followed by a unit qualifier and the quantity

Package 72789-0575-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 5, 2026.

Indications (excerpt from the label)

Anastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2 ) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3 ) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-pos…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212434

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212434
Product	Strength	Form · route	Labeler	Product NDC
Anastrozole	Anastrozole 1 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-236